Pharmena S.A. (PHR.WA)
PLN 4.39
(-0.23%)
PLN 4.39
(-0.23%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 181 Thousand PLN | -64.51% |
| 2022 | 510 Thousand PLN | -34.78% |
| 2021 | 782 Thousand PLN | 101.03% |
| 2020 | 389 Thousand PLN | -20.45% |
| 2019 | 489 Thousand PLN | -54.13% |
| 2018 | 1.06 Million PLN | -70.65% |
| 2017 | 3.63 Million PLN | -17.68% |
| 2016 | 4.41 Million PLN | 7.71% |
| 2015 | 4.09 Million PLN | 300.78% |
| 2014 | 1.02 Million PLN | 5911.76% |
| 2013 | 17 Thousand PLN | 0.0% |
| 2012 | - PLN | 0.0% |
| 2011 | - PLN | 0.0% |
| 2010 | - PLN | 0.0% |
| 2009 | - PLN | -100.0% |
| 2008 | 582.49 PLN | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 166 Thousand PLN | -8.29% |
| 2024 Q2 | 156 Thousand PLN | -8.43% |
| 2023 Q2 | 327 Thousand PLN | -25.85% |
| 2023 Q1 | 441 Thousand PLN | -13.53% |
| 2023 Q4 | 181 Thousand PLN | -45.32% |
| 2023 Q3 | 331 Thousand PLN | 1.22% |
| 2023 FY | 181 Thousand PLN | -64.51% |
| 2022 Q3 | 2.64 Million PLN | 313.59% |
| 2022 Q1 | 8.72 Million PLN | 1016.24% |
| 2022 FY | 510 Thousand PLN | -34.78% |
| 2022 Q4 | 510 Thousand PLN | -80.73% |
| 2022 Q2 | 640 Thousand PLN | -92.67% |
| 2021 Q2 | 223 Thousand PLN | -28.06% |
| 2021 Q4 | 782 Thousand PLN | -6.24% |
| 2021 FY | 782 Thousand PLN | 101.03% |
| 2021 Q1 | 310 Thousand PLN | -20.31% |
| 2021 Q3 | 834 Thousand PLN | 273.99% |
| 2020 Q3 | 4.54 Million PLN | 713.6% |
| 2020 Q4 | 389 Thousand PLN | -91.45% |
| 2020 Q2 | 559 Thousand PLN | -14.92% |
| 2020 Q1 | 657 Thousand PLN | 34.36% |
| 2020 FY | 389 Thousand PLN | -20.45% |
| 2019 Q3 | 578 Thousand PLN | -10.11% |
| 2019 Q1 | 637 Thousand PLN | -40.24% |
| 2019 Q4 | 489 Thousand PLN | -15.4% |
| 2019 FY | 489 Thousand PLN | -54.13% |
| 2019 Q2 | 643 Thousand PLN | 0.94% |
| 2018 Q2 | 3.15 Million PLN | -6.63% |
| 2018 FY | 1.06 Million PLN | -70.65% |
| 2018 Q4 | 1.06 Million PLN | -61.07% |
| 2018 Q3 | 2.73 Million PLN | -13.24% |
| 2018 Q1 | 3.38 Million PLN | -6.94% |
| 2017 Q4 | 3.63 Million PLN | -9.94% |
| 2017 Q3 | 4.03 Million PLN | -2.3% |
| 2017 Q1 | 4.14 Million PLN | -6.14% |
| 2017 FY | 3.63 Million PLN | -17.68% |
| 2017 Q2 | 4.12 Million PLN | -0.31% |
| 2016 Q1 | 2.47 Million PLN | -39.6% |
| 2016 Q2 | 4.63 Million PLN | 87.15% |
| 2016 Q4 | 4.41 Million PLN | -7.62% |
| 2016 FY | 4.41 Million PLN | 7.71% |
| 2016 Q3 | 4.77 Million PLN | 3.15% |
| 2015 Q2 | 3.28 Million PLN | 705.39% |
| 2015 Q1 | 408 Thousand PLN | -60.08% |
| 2015 FY | 4.09 Million PLN | 300.78% |
| 2015 Q4 | 4.09 Million PLN | 7.76% |
| 2015 Q3 | 3.8 Million PLN | 15.67% |
| 2014 Q2 | 93 Thousand PLN | -96.52% |
| 2014 FY | 1.02 Million PLN | 5911.76% |
| 2014 Q4 | 1.02 Million PLN | -45.67% |
| 2014 Q3 | 1.88 Million PLN | 1922.58% |
| 2014 Q1 | 2.67 Million PLN | 15641.18% |
| 2013 Q1 | - PLN | -100.0% |
| 2013 FY | 17 Thousand PLN | 0.0% |
| 2013 Q3 | 21 Thousand PLN | 0.0% |
| 2013 Q4 | 17 Thousand PLN | -19.05% |
| 2012 FY | - PLN | 0.0% |
| 2012 Q4 | 40 Thousand PLN | 0.0% |
| 2011 FY | - PLN | 0.0% |
| 2010 FY | - PLN | 0.0% |
| 2009 FY | - PLN | -100.0% |
| 2008 FY | 582.49 PLN | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioceltix S.A. | 175.05 Thousand PLN | -3.395% |
| BIOTON S.A. | 68.69 Million PLN | 99.737% |
| Captor Therapeutics Spolka Akcyjna | 3.77 Million PLN | 95.209% |
| Mabion S.A. | 35.82 Million PLN | 99.495% |
| Molecure S.A. | 7.13 Million PLN | 97.465% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Poltreg S.A. | 8.19 Million PLN | 97.791% |
| Pure Biologics Spólka Akcyjna | 12.93 Million PLN | 98.601% |
| Ryvu Therapeutics S.A. | 906 Thousand PLN | 80.022% |
| Synthaverse S.A. | 70.04 Million PLN | 99.742% |
| Urteste S.A. | 627 Thousand PLN | 71.132% |